Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status.
- DOI
- 10.3389/fonc.2026.1748566
- Published
- 2026
- Container
- Frontiers in oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fonc.2026.1748566,
title = {Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status.},
author = {Brose MS and Keam B and Krajewska J and Hoff AO and Vaisman F and Lin CC and Hitre E and Bowles DW and Robinson B and Sherman SI and Ngamphaiboon N and Guo X and Simmons A and Williamson D and Andrianova S and Berry N and Capdevila J},
year = {2026},
journal = {Frontiers in oncology},
doi = {10.3389/fonc.2026.1748566},
url = {https://doi.org/10.3389/fonc.2026.1748566}
}RIS
TY - JOUR TI - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status. AU - Brose MS AU - Keam B AU - Krajewska J AU - Hoff AO AU - Vaisman F AU - Lin CC AU - Hitre E AU - Bowles DW AU - Robinson B AU - Sherman SI AU - Ngamphaiboon N AU - Guo X AU - Simmons A AU - Williamson D AU - Andrianova S AU - Berry N AU - Capdevila J PY - 2026 JO - Frontiers in oncology DO - 10.3389/fonc.2026.1748566 UR - https://doi.org/10.3389/fonc.2026.1748566 ER -
APA
MS, B., B, K., J, K., AO, H., F, V., CC, L., E, H., DW, B., B, R., SI, S., N, N., X, G., A, S., D, W., S, A., N, B., & J, C. (2026). Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status.. Frontiers in oncology. https://doi.org/10.3389/fonc.2026.1748566
Source records
- pubmed · retrieved 2026-09-26T17:32:07.644Z
- europe-pmc · retrieved 2026-09-26T17:32:07.660Z
- doaj · retrieved 2026-09-26T17:32:07.650Z